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BACKGROUND
Lenalidomide plus dexamethasone is a standard treatment for patients with newly 
diagnosed multiple myeloma who are ineligible for autologous stem-cell transplan-
tation. We sought to determine whether the addition of daratumumab would 
significantly reduce the risk of disease progression or death in this population.
METHODS
We randomly assigned 737 patients with newly diagnosed multiple myeloma who 
were ineligible for autologous stem-cell transplantation to receive daratumumab 
plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and 
dexamethasone alone (control group). Treatment was to continue until the occur-
rence of disease progression or unacceptable side effects. The primary end point 
was progression-free survival.
RESULTS
At a median follow-up of 28.0 months, disease progression or death had occurred 
in 240 patients (97 of 368 patients [26.4%] in the daratumumab group and 143 of 
369 patients [38.8%] in the control group). The estimated percentage of patients 
who were alive without disease progression at 30 months was 70.6% (95% confi-
dence interval [CI], 65.0 to 75.4) in the daratumumab group and 55.6% (95% CI, 
49.5 to 61.3) in the control group (hazard ratio for disease progression or death, 
0.56; 95% CI, 0.43 to 0.73; P<0.001). The percentage of patients with a complete 
response or better was 47.6% in the daratumumab group and 24.9% in the control 
group (P<0.001). A total of 24.2% of the patients in the daratumumab group, as 
compared with 7.3% of the patients in the control group, had results below the 
threshold for minimal residual disease (1 tumor cell per 105 white cells) (P<0.001). 
The most common adverse events of grade 3 or 4 were neutropenia (50.0% in the 
daratumumab group vs. 35.3% in the control group), anemia (11.8% vs. 19.7%), 
lymphopenia (15.1% vs. 10.7%), and pneumonia (13.7% vs. 7.9%).
CONCLUSIONS
Among patients with newly diagnosed multiple myeloma who were ineligible for 
autologous stem-cell transplantation, the risk of disease progression or death was 
significantly lower among those who received daratumumab plus lenalidomide 
and dexamethasone than among those who received lenalidomide and dexameth-
asone alone. A higher incidence of neutropenia and pneumonia was observed in 
the daratumumab group. (Funded by Janssen Research and Development; MAIA 
ClinicalTrials.gov number, NCT02252172.)
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Multiple myeloma is a hematologic cancer in which clonal plasma-cell pro-liferation leads to complications and 
death.1 Initial treatment for newly diagnosed 
multiple myeloma depends on whether a patient 
may have unacceptable toxic effects from high-
dose chemotherapy and may be unable to under-
go autologous stem-cell transplantation.1 Younger 
patients without substantial coexisting condi-
tions usually receive an induction regimen fol-
lowed by high-dose chemotherapy and autolo-
gous stem-cell transplantation.2 For patients who 
are ineligible for stem-cell transplantation, multi-
agent regimens, including alkylating agents, 
glucocorticoids, immunomodulatory drugs, pro-
teasome inhibitors, and new agents, are the 
standard of care.2-5
Daratumumab, a human IgGκ monoclonal 
antibody that targets CD38, has direct antitumor 
and immunomodulatory activity.6-10 Initial ap-
proval of daratumumab as monotherapy for pa-
tients with heavily pretreated myeloma was based 
on the phase 1/2 GEN501 and SIRIUS trials.11,12 
Subsequently, daratumumab in combination 
with standard-of-care therapy showed clinical 
benefit across phase 3 trials involving patients 
with newly diagnosed myeloma (the ALCYONE 
trial) and patients with relapsed or refractory 
myeloma (the CASTOR and POLLUX trials).13-15 
In the POLLUX trial, treatment with daratumu-
mab plus lenalidomide and dexamethasone re-
sulted in a risk of disease progression or death 
that was 63% lower than the risk with lenalido-
mide and dexamethasone alone.15 After a median 
follow-up of 44.3 months, the median progres-
sion-free survival was 44.5 months in the dara-
tumumab group, as compared with 17.5 months 
in the control group, with no new safety con-
cerns observed.16
In the phase 3 Frontline Investigation of Rev-
limid and Dexamethasone versus Standard Tha-
lidomide (FIRST) trial5,17 involving patients with 
newly diagnosed multiple myeloma who were 
ineligible for autologous stem-cell transplanta-
tion, treatment with lenalidomide and dexameth-
asone administered until disease progression 
resulted in significantly longer overall survival 
than treatment with melphalan, prednisone, and 
thalidomide; these findings established the reg-
imen of lenalidomide and dexamethasone as 
standard of care. Here, we report the results of 
a prespecified interim analysis of a phase 3 trial 
(MAIA) in which we assessed the efficacy and 
safety of daratumumab plus lenalidomide and 
dexamethasone as compared with lenalidomide 
and dexamethasone alone in patients with newly 
diagnosed myeloma who were ineligible for 
autologous stem-cell transplantation.
Me thods
Trial Design and Oversight
In this randomized, open-label, phase 3 trial, 
patients were enrolled from March 2015 through 
January 2017 at 176 sites in 14 countries across 
North America, Europe, the Middle East, and the 
Asia–Pacific region. The independent ethics com-
mittee or institutional review board at each site 
approved the protocol, available with the full 
text of this article at NEJM.org. The trial was 
conducted in accordance with the principles of 
the Declaration of Helsinki and the Interna-
tional Conference on Harmonisation Good Clin-
ical Practice guidelines. All the patients provided 
written informed consent. The trial was designed 
by the authors in collaboration with the sponsor, 
Janssen Research and Development. The sponsor 
compiled and maintained the data and funded 
professional medical writers to prepare the manu-
script for submission. The authors reviewed and 
approved the manuscript. The sponsor and the 
authors vouch for the accuracy and completeness 
of the data and for the fidelity of the trial to the 
protocol.
Patients
Eligible patients had documented newly diag-
nosed multiple myeloma,18 had an Eastern Coop-
erative Oncology Group performance status score 
of 0 to 2 (on a 5-point scale, with higher num-
bers indicating greater disability), and were in-
eligible for high-dose chemotherapy with stem-
cell transplantation owing to age (≥65 years) or 
to the presence of coexisting conditions that 
were likely to result in the development of unac-
ceptable side effects associated with high-dose 
chemotherapy with stem-cell transplantation. 
Other inclusion criteria were a hemoglobin level 
of 7.5 g or more per deciliter, an absolute neu-
trophil count of 1000 or more per cubic millime-
ter, a platelet count of 70,000 or more per cubic 
millimeter (>50,000 per cubic millimeter if ≥50% 
of nucleated bone marrow cells were plasma 
cells), aspartate aminotransferase and alanine 
aminotransferase levels no more than 2.5 times 
the upper limit of the normal range, a total bili-
The New England Journal of Medicine 
Downloaded from nejm.org on August 28, 2020. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 380;22 nejm.org May 30, 20192106
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
rubin level no more than 2.0 times the upper 
limit of the normal range, creatinine clearance 
of 30 ml or more per minute, and a corrected 
serum calcium level of 14 mg or less per deciliter 
(3.5 mmol or less per liter). Additional eligibility 
criteria are listed in the Supplementary Appen-
dix, available at NEJM.org.
Randomization and Treatment
Using an interactive Web-response system, we 
randomly assigned patients, in a 1:1 ratio, to 
receive daratumumab plus lenalidomide and 
dexamethasone (daratumumab group) or lena-
lidomide and dexamethasone alone (control group) 
(Fig. S1 in the Supplementary Appendix). Ran-
domization was stratified according to Interna-
tional Staging System disease stage (I vs. II vs. 
III, with higher stages indicating more severe 
disease) (see Table S1 in the Supplementary Ap-
pendix for details on the staging criteria), geo-
graphic region (North America vs. other), and age 
(<75 vs. ≥75 years).
During each 28-day cycle, all the patients 
received oral lenalidomide (25 mg on days 1 
through 21) and oral dexamethasone (40 mg on 
days 1, 8, 15, and 22) until disease progression 
or unacceptable toxic effects. For patients who 
had a creatinine clearance between 30 and 50 ml 
per minute, a reduced dose of lenalidomide 
(10 mg) was recommended. Adjustment of the 
dose of lenalidomide was recommended in the 
case of neutropenia and thrombocytopenia (Ta-
ble S2 in the Supplementary Appendix). Patients 
who were older than 75 years of age or who had 
a body-mass index (the weight in kilograms di-
vided by the square of the height in meters) of 
less than 18.5 received dexamethasone at a dose 
of 20 mg once weekly. Patients in the daratumu-
mab group received intravenous daratumumab 
at a dose of 16 mg per kilogram of body weight 
once weekly during cycles 1 and 2, every 2 weeks 
during cycles 3 through 6, and every 4 weeks 
thereafter; preinfusion medications were admin-
istered approximately 1 hour before each daratu-
mumab dose (details are provided in the Supple-
mentary Appendix).
End Points and Assessments
The primary end point was progression-free sur-
vival, which was defined as the time from ran-
domization to either disease progression or death. 
Secondary efficacy end points included the time 
to progression; the percentage of patients with a 
complete response (undetectable M-protein level 
on two consecutive serum and urine immuno-
fixation tests and <5% plasma cells in bone 
marrow), a stringent complete response (com-
plete response plus a normal free light-chain 
ratio and absence of clonal plasma cells, as as-
sessed by immunofluorescence or immunohisto-
chemical analysis or by two-color to four-color 
f low cytometry), negative status for minimal 
residual disease (at a threshold of 1 tumor cell 
per 105 white cells), overall response (including 
partial response, very good partial response, com-
plete response, and stringent complete response), 
and a very good partial response (defined by a 
≥90% reduction in serum M protein plus a uri-
nary M-protein level of <100 mg per 24 hours) or 
better; overall survival; the time to response; the 
duration of response; efficacy in the subgroup of 
patients with a high-risk cytogenic profile (de-
fined by a del17p, t[14;16], or t[4;14] abnormal-
ity [or a combination of these] on fluorescence 
in situ hybridization or karyotype analysis); and 
safety. Progressive disease was defined accord-
ing to International Myeloma Working Group 
criteria (Table S3 in the Supplementary Appen-
dix).19,20 Complete definitions of these end points 
are provided in the Supplementary Appendix.
Serum samples and 24-hour urine samples 
were obtained for efficacy assessment every 28 
days for 2 years and then every 8 weeks there-
after until disease progression; all samples were 
evaluated at a central laboratory. In the case of 
patients who had positive serum immunofixation 
and daratumumab interference, complete respons-
es were confirmed with the use of reflex assays.21 
Minimal residual disease was evaluated by means 
of the Adaptive Biotechnologies clonoSEQ next-
generation sequencing assay (version 2.0) with 
the use of bone marrow aspirate obtained at 
baseline, at the time of suspected complete or 
stringent complete response, and at 12, 18, 24, 
and 30 months after the first dose in patients 
who had a complete response or better. Safety 
assessments included the evaluation of adverse 
events, which were graded according to version 4 
of the National Cancer Institute Common Termi-
nology Criteria for Adverse Events22; electrocar-
diography; clinical laboratory testing; physical 
examinations; and vital signs.
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Statistical Analysis
The primary analysis was performed in the inten-
tion-to-treat population, which included all pa-
tients who underwent randomization. The safety 
population included all patients who received at 
least one dose of the trial treatment. The pri-
mary end point of progression-free survival was 
compared between the treatment groups with 
the use of a stratified log-rank test, and the 
treatment effect (hazard ratio) and correspond-
ing 95% confidence interval were estimated with 
the use of a stratified Cox regression model, 
with treatment as the sole explanatory variable. 
Other time-to-event efficacy end points were 
analyzed similarly. Response to trial treatment 
and progressive disease were evaluated with the 
use of a validated computer algorithm.14,15 Con-
tinuous variables were summarized with the use 
of descriptive statistics, and categorical variables 
were summarized as numbers and percentages. 
Time-to-event variables were summarized with 
the use of the Kaplan–Meier method. We analyzed 
binary end points using a stratified Cochran–
Mantel–Haenszel test. If the risk of the primary 
end point was found to be significantly lower in 
the daratumumab group than in the control 
group, the following secondary end points, as 
ordered here, were to be tested sequentially: 
complete response or better, very good partial 
response or better, negative status for minimal 
residual disease, overall response, and overall 
survival. The significance level was determined 
according to the alpha-spending function spe-
cific to each end point (see the Supplementary 
Appendix). For the evaluation of overall survival, 
a modified linear alpha-spending function was 
used to determine the alpha level at the time 
of each of three analyses (the second interim 
analysis, the primary progression-free survival 
analysis, and the final overall survival analysis). 
The alpha level was 0.0001 at the time of this 
first analysis.
Of two planned interim analyses, the first 
evaluated only safety after 100 patients had re-
ceived at least 8 weeks of treatment or had dis-
continued treatment. The second, reported here, 
assessed safety and efficacy after 240 events of 
disease progression or death had occurred (i.e., 
62% of the 390 planned events for the primary 
analysis). The final overall survival analysis is 
planned to be performed after 330 deaths have 
been reported. We estimated that a sample of 
730 patients would provide the trial with 80% 
power to detect a risk of disease progression or 
death that was 25% lower with daratumumab 
plus lenalidomide and dexamethasone than with 
lenalidomide and dexamethasone alone, using a 
log-rank test at a two-sided alpha level of 0.05.
R esult s
Patients and Treatment
A total of 737 patients were randomly assigned 
— 368 to the daratumumab group and 369 to 
the control group. Demographic and clinical 
characteristics of the two groups were well bal-
anced at baseline (Table 1). The median age was 
73 years (range, 45 to 90), and 14.3% of patients 
had a high-risk cytogenetic profile. The median 
time since the diagnosis of multiple myeloma 
was 0.9 months (range, 0 to 14.5).
Among the patients who underwent random-
ization, 729 patients (364 in the daratumumab 
group and 365 in the control group) received at 
least one dose of the trial treatment (Fig. S2 in 
the Supplementary Appendix). At the time of the 
clinical data cutoff for the primary analysis 
(September 24, 2018), a total of 118 patients 
(32.4%) in the daratumumab group and 207 
patients (56.7%) in the control group had dis-
continued treatment, most commonly because of 
progressive disease (14.6% in the daratumumab 
group and 23.8% in the control group) and ad-
verse events (7.4% and 16.2%, respectively). Pa-
tients who discontinued treatment for reasons 
other than disease progression and remained 
in the trial were followed for the primary end 
point.
The median duration of treatment was 25.3 
months (range, 0.1 to 40.4) in the daratumumab 
group and 21.3 months (range, 0.03 to 40.6) in 
the control group, and the median number of 
treatment cycles was 27 (range, 1 to 44) in the 
daratumumab group and 22 (range, 1 to 43) in 
the control group (Table S4 in the Supplemen-
tary Appendix). The median relative dose inten-
sity (see the Supplementary Appendix for defini-
tions) for daratumumab was 98.4%. The median 
relative dose intensity for lenalidomide was 
76.2% in the daratumumab group and 91.4% in 
the control group; 112 patients (30.8%) in the 
daratumumab group and 83 patients (22.7%) in 
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the control group received 10 mg or less of the 
starting dose of lenalidomide. In addition, a 
higher percentage of patients in the daratumumab 
group than in the control group had dose 
modifications of lenalidomide owing to adverse 
events that occurred after the start of treatment, 
including lenalidomide discontinuations (20.9% 
and 17.0%, respectively) or dose delays, reduc-
tions, reescalations, or skipping (combined, 
77.5% and 64.7%, respectively). The median rela-
tive dose intensity for dexamethasone was 84.2% 
in the daratumumab group and 90.7% in the 
control group.
A total of 35 patients in the daratumumab 
group discontinued treatment with lenalidomide 
and dexamethasone completely but continued to 
receive daratumumab monotherapy. The median 
duration of single-agent daratumumab treatment 
was 7.3 months (range, 0.03 to 31.2) among 
these patients.
Efficacy
At a median follow-up of 28.0 months (range, 0 to 
41.4), disease progression or death had occurred 
in 240 patients (97 of 368 patients [26.4%] in the 
daratumumab group and 143 of 369 patients 
[38.8%] in the control group). The Kaplan–Meier 
estimate of the percentage of patients who were 
alive without disease progression at 30 months 
was 70.6% (95% confidence interval [CI], 65.0 to 
75.4) in the daratumumab group and 55.6% 
(95% CI, 49.5 to 61.3) in the control group. The 
median progression-free survival was not reached 
in the daratumumab group and was 31.9 months 
(95% CI, 28.9 to not reached) in the control 
group. The hazard ratio for disease progression 
or death in the daratumumab group as com-
pared with the control group was 0.56 (95% CI, 
0.43 to 0.73; P<0.001) (Fig. 1).
Prespecified subgroup analyses of progression-
free survival confirmed the superiority of the 
daratumumab regimen over the control regimen 
across all subgroups, except in the subgroup of 
patients who had hepatic impairment at baseline 
(Fig. 2). The progression-free survival benefit was 
maintained among patients 75 years of age or 
older (hazard ratio, 0.63; 95% CI, 0.44 to 0.92).
In the intention-to-treat population, the per-
centage of patients with a complete response or 
better was significantly higher in the daratumu-
mab group than in the control group (47.6% vs. 
24.9%), as was the percentage with very good 
partial response or better (79.3% vs. 53.1%) 








Median age (range) — yr 73.0 (50–90) 74.0 (45–89)
Age category — no. (%)
<65 yr 4 (1.1) 4 (1.1)
65 to <70 yr 74 (20.1) 73 (19.8)
70 to <75 yr 130 (35.3) 131 (35.5)
≥75 yr 160 (43.5) 161 (43.6)
ECOG performance status — no. (%)†
0 127 (34.5) 123 (33.3)
1 178 (48.4) 187 (50.7)
2‡ 63 (17.1) 59 (16.0)
ISS disease stage — no. (%)§
I 98 (26.6) 103 (27.9)
II 163 (44.3) 156 (42.3)
III 107 (29.1) 110 (29.8)
Type of measurable disease — no. (%)
IgG 225 (61.1) 231 (62.6)
IgA 65 (17.7) 66 (17.9)
Other¶ 9 (2.4) 10 (2.7)
Detected in urine only 40 (10.9) 34 (9.2)
Detected as serum free light-chain 
only
29 (7.9) 28 (7.6)
Cytogenetic profile — no./total no. (%)‖
Standard risk 271/319 (85.0) 279/323 (86.4)
High risk 48/319 (15.0) 44/323 (13.6)
Median time since initial diagnosis of 
multiple myeloma (range) — mo
0.95 (0.1–13.3) 0.89 (0–14.5)
*  The intention-to-treat population included all patients who underwent random-
ization. Post hoc analyses showed no significant differences between the two 
groups in the characteristics evaluated at baseline.
†  Eastern Cooperative Oncology Group (ECOG) performance status is scored 
on a scale from 0 to 5, with 0 indicating no symptoms and higher scores in-
dicating increasing disability.
‡  Two patients had a score of greater than 2 (one patient had a score of 3, and 
another patient had a score of 4).
§  The International Staging System (ISS) disease stage, which is derived on the 
basis of the combination of serum β2-microglobulin and albumin levels, con-
sists of three stages. Higher stages indicate more severe disease.
¶  This category includes IgD, IgE, IgM, and biclonal.
‖  Cytogenetic risk was based on fluorescence in situ hybridization or karyotype 
analysis; patients who had a high-risk cytogenetic profile had at least one 
high-risk abnormality (del17p, t[14;16], or t[4;14]).
Table 1. Demographic and Baseline Disease Characteristics in the Intention-
to-Treat Population.*
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percentage of patients with an overall response 
was 92.9% in the daratumumab group and 
81.3% in the control group (P<0.001).
The percentage of patients who were negative 
for minimal residual disease (at a threshold of 
1 tumor cell per 105 white cells) was more than 
3 times as high in the daratumumab group as in 
the control group (24.2% vs. 7.3%, P<0.001) 
(Table 2). Negative status for minimal residual 
disease was associated with longer progression-
free survival than positive status, regardless of 
the trial treatment (Fig. S3 in the Supplementary 
Appendix). All the patients who were negative 
for minimal residual disease had a complete re-
sponse or better.
At a median follow-up of 28.0 months, 138 pa-
tients had died — 62 (16.8%) in the daratumu-
mab group and 76 (20.6%) in the control group 
(Fig. S4 in the Supplementary Appendix). The 
median overall survival was not reached in either 
group, and follow-up for long-term survival is 
ongoing.
Among the patients who had a response (par-
tial response or better), 80.3% (95% CI, 75.1 to 
84.5) in the daratumumab group and 65.7% 
(95% CI, 58.6 to 71.8) in the control group sus-
tained the response for 30 months. The median 
time to the first response was 1.05 months in 
both groups, and the median time to a complete 
response or better was 10.4 months in the dara-
tumumab group and 11.2 months in the control 
group. The percentage of patients who were 
negative for minimal residual disease increased 
over time at a higher rate in the daratumumab 
group than in the control group (Fig. S5 in the 
Supplementary Appendix).
Safety
Table 3 summarizes the most common adverse 
events of any grade (in >30% of patients in either 
group) and the most common adverse events of 
grade 3 or 4 (in >10% of patients in either group) 
during treatment in the safety population. The 
most common adverse events of grade 3 or 4 were 
neutropenia (50.0% in the daratumumab group 
and 35.3% in the control group), anemia (11.8% 
and 19.7%), lymphopenia (15.1% and 10.7%), 
pneumonia (13.7% and 7.9%), and leukopenia 
(11.0% and 4.9%). The incidence of infections of 
any grade was 86.3% in the daratumumab group 
Figure 1. Progression-free Survival.
Shown are the results of the Kaplan–Meier estimates of progression-free survival among patients in the intention-to-
treat population. The daratumumab group received treatment with daratumumab, lenalidomide, and dexamethasone; 
the control group received treatment with lenalidomide and dexamethasone. The interim analysis of progression-
free survival was performed after 240 events of disease progression or death had occurred (62% of the planned  
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and 73.4% in the control group; the incidence of 
grade 3 or 4 infections was 32.1% in the daratum-
umab group and 23.3% in the control group.
Serious adverse events were reported in 62.9% 
of the patients in the daratumumab group and 
in 62.7% of the patients in the control group. 
Pneumonia was the most common serious ad-
verse event, occurring in 13.2% of the patients 
in the daratumumab group and in 7.4% of the 
patients in the control group. The percentage of 
Figure 2. Prespecified Subgroup Analysis of Progression-free Survival.
Shown are the results of an analysis of progression-free survival in prespecified subgroups in the intention-to-treat population. The dara-
tumumab group received treatment with daratumumab, lenalidomide, and dexamethasone; the control group received treatment with lena-
lidomide and dexamethasone. The International Staging System (ISS) disease stage, which is derived on the basis of the combination  
of serum β2-microglobulin and albumin levels, consists of three stages, with higher stages indicating more advanced disease. The sub-
group analysis for the type of myeloma was performed on data from patients who had measurable disease in serum. A high-risk cytoge-
netic profile was defined by the detection of a del17p, t(14;16), or t(4;14) cytogenetic abnormality (or a combination of these) on fluores-
cence in situ hybridization or karyotype analysis. Impaired baseline hepatic function includes mild impairment (total bilirubin level less 
than or equal to the upper limit of the normal range [ULN] and aspartate aminotransferase level higher than the ULN, or total bilirubin 
level higher than the ULN and ≤1.5 times the ULN), moderate impairment (total bilirubin level >1.5 times and ≤3 times the ULN), and 
severe impairment (total bilirubin level >3 times the ULN). Eastern Cooperative Oncology Group (ECOG) performance status is scored on 
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patients who had adverse events that led to dis-
continuation of the trial treatment was 7.1% in 
the daratumumab group and 15.9% in the con-
trol group. Discontinuation of the trial treatment 
owing to an infection occurred in 0.5% of the 
patients in the daratumumab group and in 1.4% 
of the patients in the control group; no patients 
in the daratumumab group, as compared with 
1 patient (0.3%) in the control group, discontin-
ued treatment because of neutropenia.
Adverse events that resulted in death were ob-
served in 25 patients (6.9%) in the daratumumab 
group and in 23 patients (6.3%) in the control 
group; the most common such event was pneu-
monia, which resulted in death in 0.5% and 
0.8% of the patients, respectively. Invasive sec-
ond primary cancers occurred in 12 patients 
(3.3%) in the daratumumab group (solid tumors 
in 2.7% and hematologic cancers in 0.5%) and 
in 13 patients (3.6%) in the control group (solid 
tumors in 3.0% and hematologic cancers in 0.5%).
Infusion-related reactions associated with dara-
tumumab were reported in 40.9% of the patients 
in the daratumumab group; 2.7% of the patients 
had events of grade 3 or 4, including one patient 
who had grade 4 hypertension, and no grade 5 
events were reported (Table S5 in the Supple-
mentary Appendix). Infusion-related reactions 
usually occurred during administration of the 
first dose (in 98.0% of the patients who had 
such reactions), and only one patient (the patient 
who had grade 4 hypertension) discontinued 
daratumumab treatment after an infusion-related 
reaction.
Discussion
The results of this phase 3 trial showed that 
among patients with newly diagnosed multiple 
myeloma who were ineligible for stem-cell trans-
plantation, treatment with daratumumab plus 





(N = 369) P Value
Overall response — no. (% [95% CI]) 342 (92.9 [89.8–95.3]) 300 (81.3 [76.9–85.1]) <0.001†
Best overall response — no. (%)
Complete response or better 175 (47.6) 92 (24.9) <0.001†
Stringent complete response‡ 112 (30.4) 46 (12.5) —
Complete response 63 (17.1) 46 (12.5) —
Very good partial response or better 292 (79.3) 196 (53.1) <0.001†
Very good partial response 117 (31.8) 104 (28.2) —
Partial response 50 (13.6) 104 (28.2) —
Stable disease 11 (3.0) 56 (15.2) —
Progressive disease 1 (0.3) 0 —
Response could not be evaluated 14 (3.8) 13 (3.5) —
Negative status for minimal residual disease 
— no. (%)§
89 (24.2) 27 (7.3) <0.001¶
*  Response was assessed on the basis of International Myeloma Working Group recommendations (details on the crite-
ria for disease responses are provided in the protocol). The following secondary end points were tested sequentially, 
each with an overall two-sided alpha level of 0.05, with the use of a hierarchical testing approach: complete response or 
better, very good partial response or better, negative status for minimal residual disease, and overall response.
†  The P value was calculated with the use of the Cochran–Mantel–Haenszel chi-square test.
‡  Criteria for a stringent complete response include the criteria for a complete response plus a normal free light-chain ra-
tio and absence of clonal plasma cells, as assessed by immunofluorescence or immunohistochemical analysis or by 
two-color to four-color flow cytometry.
§  The threshold for minimal residual disease was defined as 1 tumor cell per 105 white cells. Status regarding minimal 
residual disease is based on a postrandomization assessment performed on bone marrow samples with the use of a 
validated next-generation sequencing assay (clonoSEQ Assay, version 2.0; Adaptive Biotechnologies) in accordance 
with International Myeloma Working Group guidelines on assessment of minimal residual disease.23
¶  The P value was calculated with the use of the Fisher’s exact test.
Table 2. Summary of Response Rates and Minimal Residual Disease Status in the Intention-to-Treat Population.*
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significantly longer progression-free survival than 
lenalidomide and dexamethasone alone; the risk 
of disease progression or death was 44% lower 
in the daratumumab group than in the control 
group. These findings can be added to those 
from a growing list of trials that support the use 
of daratumumab-based regimens across patient 
populations with multiple myeloma.13-16,24,25 In our 
trial, the percentage of patients with a complete 
response or better was nearly twice as high and 
the percentage of patients who were negative for 
minimal residual disease was more than 3 times 
as high in the daratumumab group as in the 
control group; these findings are consistent with 
those of previous trials. We anticipate that re-
sponses in individual patients, including nega-
tive status for minimal residual disease, will 
deepen over time, as has been observed with 
other daratumumab-containing regimens.26,27
The results of this interim analysis showed 
that the benefit of daratumumab with respect to 
progression-free survival was not as high in the 
subgroup of patients who had a high-risk cyto-
genetic profile as it was in the subgroup of pa-
tients who had a standard-risk cytogenetic pro-
file. However, in the CASTOR and POLLUX trials, 
among patients with relapsed or refractory mul-
tiple myeloma who had a high-risk cytogenetic 
profile, substantial benefits with respect to 
progression-free survival and minimal residual 
disease with daratumumab plus standard-of-care 
regimens were observed after a longer follow-up 
period.16,25






Any Grade Grade 3 or 4 Any Grade Grade 3 or 4
number of patients (percent)
Hematologic adverse events
Neutropenia 207 (56.9) 182 (50.0) 154 (42.2) 129 (35.3)
Anemia 126 (34.6) 43 (11.8) 138 (37.8) 72 (19.7)
Leukopenia 68 (18.7) 40 (11.0) 34 (9.3) 18 (4.9)
Lymphopenia 66 (18.1) 55 (15.1) 45 (12.3) 39 (10.7)
Nonhematologic adverse events
Infections 314 (86.3) 117 (32.1) 268 (73.4) 85 (23.3)
Pneumonia 82 (22.5) 50 (13.7) 46 (12.6) 29 (7.9)
Diarrhea 207 (56.9) 24 (6.6) 168 (46.0) 15 (4.1)
Constipation 149 (40.9) 6 (1.6) 130 (35.6) 1 (0.3)
Fatigue 147 (40.4) 29 (8.0) 104 (28.5) 14 (3.8)
Peripheral edema 140 (38.5) 7 (1.9) 107 (29.3) 2 (0.5)
Back pain 123 (33.8) 11 (3.0) 96 (26.3) 11 (3.0)
Asthenia 117 (32.1) 16 (4.4) 90 (24.7) 13 (3.6)
Nausea 115 (31.6) 5 (1.4) 84 (23.0) 2 (0.5)
Second primary cancer† 32 (8.8) NA 26 (7.1) NA
Invasive second primary cancer 12 (3.3) NA 13 (3.6) NA
Any infusion-related reaction 149 (40.9) 10 (2.7) NA NA
*  The safety population included all patients who received at least one dose of the trial treatment. Adverse events of any 
grade that were reported in more than 30% of patients in either treatment group and grade 3 or 4 adverse events that 
were reported in more than 10% of patients in either treatment group are listed. NA denotes not applicable.
†  The presence of a second primary cancer was prespecified in the statistical analysis plan as an adverse event of clinical 
interest.
Table 3. Most Common Adverse Events and Second Primary Cancers Reported during Treatment in the Safety 
Population.*
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ences in patient populations and trial designs 
but are important to contextualize our findings. 
The phase 3 Southwest Oncology Group (SWOG) 
S0777 trial of lenalidomide plus dexamethasone 
with or without bortezomib in patients with 
newly diagnosed myeloma for whom immediate 
autologous stem-cell transplantation was not in-
dicated showed that the triplet combination re-
sulted in longer progression-free survival (median, 
41 months vs. 29 months; hazard ratio, 0.74), 
including among patients who were 65 years of 
age or older (43% of the trial population; median, 
34 months vs. 24 months) and among patients 
who were older than 75 years of age (median, 34 
months vs. 17 months).4,28 Our trial population 
was notably older; 99% of the patients were 65 
years of age or older, and 44% were 75 years of 
age or older. The median progression-free sur-
vival benefit in the daratumumab group in our 
trial was maintained for patients 75 years of age 
or older (hazard ratio, 0.63); the hazard ratio ob-
served in the FIRST trial — in which lenalidomide 
and dexamethasone administered until disease 
progression was compared with melphalan, pred-
nisone, and thalidomide — was 0.78 in the 
subgroup of patients older than 75 years of age.17 
Progression-free survival was longer in the con-
trol group of our trial than in the similarly 
treated group in the FIRST trial, a finding that 
may be attributed to the longer median duration 
of treatment observed in the control group in our 
trial (21.3 months in our trial vs. 18.4 months in 
the FIRST trial).5
The median duration of treatment was longer 
in the daratumumab group than in the control 
group (25.3 months vs. 21.3 months). Although 
patients in the daratumumab group received 
treatment for a longer period of time, they re-
ceived less lenalidomide than the control group, 
possibly owing to a higher incidence of adverse 
events that led to dose discontinuations or dose 
modifications in this group. Nevertheless, the 
efficacy of the daratumumab-based regimen was 
not affected by the lower dose of lenalidomide, 
as shown by the consistent progression-free sur-
vival benefit in the subgroup of patients who 
had a baseline creatinine clearance level of 60 ml 
or less per minute.
The daratumumab group had a higher inci-
dence of neutropenia and infections (including 
pneumonia) than the control group. However, the 
incidence of grade 3 or 4 infections was 29% with 
lenalidomide and dexamethasone in the primary 
analysis of the FIRST trial,5 which was consis-
tent with the incidence in our trial (32.1% in the 
daratumumab group and 23.3% in the control 
group). The percentage of patients who discon-
tinued treatment because of these adverse events 
was low in our trial and was consistent with 
the safety profile observed in the POLLUX and 
ALCYONE trials, the latter of which represents a 
similar population of patients with newly diag-
nosed myeloma who were ineligible for stem-cell 
transplantation.
In this trial involving patients with newly 
diagnosed multiple myeloma who were ineligi-
ble for stem-cell transplantation, the addition of 
daratumumab to lenalidomide and dexametha-
sone resulted in significantly longer progression-
free survival, a higher response rate, an increased 
depth of response, and a longer duration of re-
sponse than lenalidomide and dexamethasone 
alone. Daratumumab plus lenalidomide and dexa-
methasone was associated with a higher inci-
dence of neutropenia and infections.
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